Bristol-Myers Squibb cut to market perform from outperform; target price lowered to $59 from $73
BMY•Leerink Partners cut Bristol-Myers Squibb to market perform from outperform and lowered its target price to $59 from $73.
Related News
Kratos Defense wins over $100 million in space, cyber mission contracts
KTOS•
Sabine Royalty Trust announces monthly cash distribution for October 2026
SBR•
Prismic Life announces $5 billion reinsurance agreement with Prudential Financial
PRU•
4D Molecular Therapeutics to host investor day webcast
FDMT•
C.H. Robinson says RXO would owe $175 million fee under certain merger termination circumstances
CHRW•